Antiarrhythmic effects and mechanisms of sodium-glucose cotransporter 2 inhibitors: A mini review

被引：7
|
作者：
Wu, Jinchun [1 ]
Liu, Yanmin [1 ]
Wei, Xiaojuan [1 ]
Zhang, Xiaofei [1 ]
Ye, Yi [2 ]
Li, Wei [1 ]
Su, Xiaoling [1 ]
机构：
[1] Qinghai Prov Peoples Hosp, Dept Cardiol, Xining, Peoples R China
[2] Qinghai Univ, Grad Sch, Xining, Peoples R China
来源：
FRONTIERS IN CARDIOVASCULAR MEDICINE | 2022年 / 9卷
关键词：
Na+ homeostasis; Ca2+ homeostasis; Na+-H+ exchanger regulatory factor (NHERF)1; 2; Na+-Ca2+ exchanger (NCX); ventricular arrhythmia (VAs); atrial fibrillation; arrhythmia; sodium-glucose cotransporter 2 inhibitor; SUDDEN CARDIAC DEATH; SGLT2; INHIBITORS; HEART-FAILURE; VENTRICULAR-ARRHYTHMIAS; DIASTOLIC DYSFUNCTION; ATRIAL-FIBRILLATION; ARTERIAL STIFFNESS; NA+/H+ EXCHANGER; BLOOD-PRESSURE; EMPAGLIFLOZIN;
D O I：
10.3389/fcvm.2022.915455
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are a new type of oral hypoglycaemic agent with good cardiovascular protective effects. There are several lines of clinical evidence suggest that SGLT2i can significantly reduce the risks of heart failure, cardiovascular death, and delay the progression of chronic kidney disease. In addition, recent basic and clinical studies have also reported that SGLT2i also has good anti-arrhythmic effects. However, the exact mechanism is poorly understood. The aim of this review is to summarize recent clinical findings, studies of laboratory animals, and related study about this aspect of the antiarrhythmic effects of SGLT2i, to further explore its underlying mechanisms, safety, and prospects for clinical applications of it.
引用
收藏
页数：10
相关论文
共 50 条
  • [31] Sodium-glucose cotransporter 2 inhibitors and emphysematous cystitis
    Dubin, Ina
    Glick, Yair
    Schattner, Ami
    POSTGRADUATE MEDICAL JOURNAL, 2024, 100 (1190) : 946 - 947
  • [32] Benefits and Complications of Sodium-Glucose Cotransporter 2 Inhibitors
    Sangiovanni, Ryan J.
    DeVee, Carley E.
    US PHARMACIST, 2019, 44 (02) : HS9 - HS12
  • [33] Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure
    Shah, Kevin S.
    Fang, James C.
    ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 2022, 62 : 109 - 120
  • [34] Sodium-glucose cotransporter 2 inhibitors and risk of nephrolithiasis
    Kristensen, Kasper B.
    Henriksen, Daniel P.
    Hallas, Jesper
    Pottegard, Anton
    Lund, Lars C.
    DIABETOLOGIA, 2021, 64 (07) : 1563 - 1571
  • [35] Sodium-Glucose Cotransporter-2 Inhibitors in Depression
    Liebers, David T.
    Ebina, Wataru
    Iosifescu, Dan V.
    HARVARD REVIEW OF PSYCHIATRY, 2023, 31 (04) : 214 - 221
  • [36] Sodium-glucose cotransporter 2 inhibitors and diabetic ketoacidosis
    Bloomgarden, Zachary T.
    JOURNAL OF DIABETES, 2016, 8 (02) : 175 - 176
  • [37] Sodium-glucose cotransporter 2 inhibitors and renal function
    Bloomgarden, Zachary
    JOURNAL OF DIABETES, 2015, 7 (03) : 295 - 298
  • [38] Sodium-glucose cotransporter 2 inhibitors and skeletal muscle
    Coats, Andrew J. Stewart
    EUROPEAN JOURNAL OF HEART FAILURE, 2024, 26 (04) : 936 - 937
  • [39] Sodium-glucose cotransporter 2 inhibitors and cardiovascular outcomes
    Steinberg, Helmut O.
    POSTGRADUATE MEDICINE, 2016, 128 (04) : 398 - 408
  • [40] Sodium-Glucose Cotransporter 2 Inhibitors and Cardiac Remodeling
    Salah, Husam M.
    Verma, Subodh
    Santos-Gallego, Carlos G.
    Bhatt, Ankeet S.
    Vaduganathan, Muthiah
    Khan, Muhammad Shahzeb
    Lopes, Renato D.
    Al'Aref, Subhi J.
    McGuire, Darren K.
    Fudim, Marat
    JOURNAL OF CARDIOVASCULAR TRANSLATIONAL RESEARCH, 2022, 15 (05) : 944 - 956
12345